Literature DB >> 10100314

The effect of in vivo dissolution, gastric emptying rate, and intestinal transit time on the peak concentration and area-under-the-curve of drugs with different gastrointestinal permeabilities.

L C Kaus1, W R Gillespie, A S Hussain, G L Amidon.   

Abstract

PURPOSE: To theoretically investigate the impact of gastric emptying half-time, intestinal transit time and the time for 85% in vivo dissolution on the peak concentration and area-under-the curve of model drugs.
METHODS: Simulations were performed using mathematical models of gastrointestinal physiology and pharmacokinetics of model drugs with different gastrointestinal permeability. They were used to investigate the effect of different permutations of gastric emptying times, intestinal transit times, dissolution rates and effective permeabilities on the maximum plasma drug concentration and the area-under-the-curve of immediate release tablets relative to an oral solution (i.e., Cmax(tablet)/Cmax(solution) and AUC(tablet)/AUC(solution)).
RESULTS: The higher the permeability of the drug, the more sensitive the Cmax ratio is to dissolution rate and gastric emptying rate. As the intestinal transit time becomes more rapid, the sensitivity to T85% dissolution time and gastric emptying half-time increases. There is less dependence for the AUC ratio on the gastric emptying time and dissolution rate.
CONCLUSIONS: Under the assumptions of the models, the criterion of 85% dissolution in 15 minutes (T85%) for classifying a rapidly dissolving drug product is relatively conservative since the Cmax ratio exceeded 0.8 for a T85% dissolution time of one hour and a gastric emptying half-time faster than 0.2 hour over a wide range of permeabilities.

Entities:  

Keywords:  Non-programmatic

Mesh:

Year:  1999        PMID: 10100314     DOI: 10.1023/a:1018836727001

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  11 in total

Review 1.  Transport approaches to the biopharmaceutical design of oral drug delivery systems: prediction of intestinal absorption.

Authors:  L X Yu; E Lipka; J R Crison; G L Amidon
Journal:  Adv Drug Deliv Rev       Date:  1996-06-12       Impact factor: 15.470

2.  Use of a pharmacokinetic model incorporating discontinuous gastrointestinal absorption to examine the occurrence of double peaks in oral concentration-time profiles.

Authors:  A B Suttle; G M Pollack; K L Brouwer
Journal:  Pharm Res       Date:  1992-03       Impact factor: 4.200

3.  The influence of variable gastric emptying and intestinal transit rates on the plasma level curve of cimetidine; an explanation for the double peak phenomenon.

Authors:  R L Oberle; G L Amidon
Journal:  J Pharmacokinet Biopharm       Date:  1987-10

4.  Transit of pharmaceutical dosage forms through the small intestine.

Authors:  S S Davis; J G Hardy; J W Fara
Journal:  Gut       Date:  1986-08       Impact factor: 23.059

5.  Physicochemical model for dose-dependent drug absorption.

Authors:  J B Dressman; D Fleisher; G L Amidon
Journal:  J Pharm Sci       Date:  1984-09       Impact factor: 3.534

6.  Comparison of intestinal permeabilities determined in multiple in vitro and in situ models: relationship to absorption in humans.

Authors:  B H Stewart; O H Chan; R H Lu; E L Reyner; H L Schmid; H W Hamilton; B A Steinbaugh; M D Taylor
Journal:  Pharm Res       Date:  1995-05       Impact factor: 4.200

7.  A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability.

Authors:  G L Amidon; H Lennernäs; V P Shah; J R Crison
Journal:  Pharm Res       Date:  1995-03       Impact factor: 4.200

8.  Estimation of oral drug absorption in man based on intestine permeability in rats.

Authors:  B Levet-Trafit; M S Gruyer; M Marjanovic; R C Chou
Journal:  Life Sci       Date:  1996       Impact factor: 5.037

9.  Predicting fraction dose absorbed in humans using a macroscopic mass balance approach.

Authors:  P J Sinko; G D Leesman; G L Amidon
Journal:  Pharm Res       Date:  1991-08       Impact factor: 4.200

10.  Regional jejunal perfusion, a new in vivo approach to study oral drug absorption in man.

Authors:  H Lennernäs; O Ahrenstedt; R Hällgren; L Knutson; M Ryde; L K Paalzow
Journal:  Pharm Res       Date:  1992-10       Impact factor: 4.200

View more
  4 in total

1.  Influence of drug release properties of conventional solid dosage forms on the systemic exposure of highly soluble drugs.

Authors:  L X Yu; C D Ellison; D P Conner; L J Lesko; A S Hussain
Journal:  AAPS PharmSci       Date:  2001

2.  Physiologically Based Pharmacokinetic and Absorption Modeling for Osmotic Pump Products.

Authors:  Zhanglin Ni; Arjang Talattof; Jianghong Fan; Eleftheria Tsakalozou; Satish Sharan; Dajun Sun; Hong Wen; Liang Zhao; Xinyuan Zhang
Journal:  AAPS J       Date:  2017-03-29       Impact factor: 4.009

Review 3.  Summary of the National Institute of Child Health and Human Development-best pharmaceuticals for Children Act Pediatric Formulation Initiatives Workshop-Pediatric Biopharmaceutics Classification System Working Group.

Authors:  Susan M Abdel-Rahman; Gordon L Amidon; Ajay Kaul; Viera Lukacova; Alexander A Vinks; Gregory T Knipp
Journal:  Clin Ther       Date:  2012-11       Impact factor: 3.393

4.  Linking the Gastrointestinal Behavior of Ibuprofen with the Systemic Exposure between and within Humans-Part 1: Fasted State Conditions.

Authors:  Marival Bermejo; Paulo Paixão; Bart Hens; Yasuhiro Tsume; Mark J Koenigsknecht; Jason R Baker; William L Hasler; Robert Lionberger; Jianghong Fan; Joseph Dickens; Kerby Shedden; Bo Wen; Jeffrey Wysocki; Raimar Löbenberg; Allen Lee; Ann Frances; Gregory E Amidon; Alex Yu; Niloufar Salehi; Arjang Talattof; Gail Benninghoff; Duxin Sun; Gislaine Kuminek; Katie L Cavanagh; Naír Rodríguez-Hornedo; Gordon L Amidon
Journal:  Mol Pharm       Date:  2018-11-12       Impact factor: 4.939

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.